In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales... Show more
On December 16, 2025, the Stochastic Oscillator for GLAXF moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 70 instances where the indicator left the oversold zone. In of the 70 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved above the 0 level on December 24, 2025. You may want to consider a long position or call options on GLAXF as a result. In of 144 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLAXF advanced for three days, in of 167 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 208 cases where GLAXF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Moving Average Convergence Divergence Histogram (MACD) for GLAXF turned negative on December 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
GLAXF broke above its upper Bollinger Band on November 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.399) is normal, around the industry mean (9.054). P/E Ratio (13.243) is within average values for comparable stocks, (24.434). Projected Growth (PEG Ratio) (0.407) is also within normal values, averaging (2.056). Dividend Yield (0.036) settles around the average of (0.026) among similar stocks. P/S Ratio (2.265) is also within normal values, averaging (3.759).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GLAXF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry PharmaceuticalsMajor
A.I.dvisor indicates that over the last year, GLAXF has been loosely correlated with GSK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GLAXF jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To GLAXF | 1D Price Change % | ||
|---|---|---|---|---|
| GLAXF | 100% | N/A | ||
| GSK - GLAXF | 37% Loosely correlated | +0.23% | ||
| OPHLY - GLAXF | 9% Poorly correlated | +0.15% | ||
| HAWPF - GLAXF | 8% Poorly correlated | +14.68% | ||
| ORINY - GLAXF | 6% Poorly correlated | N/A | ||
| GIKLY - GLAXF | 5% Poorly correlated | N/A | ||
More | ||||
| Ticker / NAME | Correlation To GLAXF | 1D Price Change % |
|---|---|---|
| GLAXF | 100% | N/A |
| Pharmaceuticals: Major industry (61 stocks) | 14% Poorly correlated | +0.75% |
| Pharmaceuticals industry (375 stocks) | 8% Poorly correlated | +0.36% |